Daily Cardiology Research Analysis
Three impactful cardiology papers stood out: an AI model accurately detecting and predicting structural heart disease from noisy single‑lead ECGs; a randomized trial showing cryoballoon ablation is non‑inferior to radiofrequency ablation for persistent atrial fibrillation; and fully automated AI analysis of handheld echocardiography delivering diagnostic accuracy for reduced LVEF comparable to expert cart-based scans. Together, they underscore scalable diagnostics and procedure selection refinem
Summary
Three impactful cardiology papers stood out: an AI model accurately detecting and predicting structural heart disease from noisy single‑lead ECGs; a randomized trial showing cryoballoon ablation is non‑inferior to radiofrequency ablation for persistent atrial fibrillation; and fully automated AI analysis of handheld echocardiography delivering diagnostic accuracy for reduced LVEF comparable to expert cart-based scans. Together, they underscore scalable diagnostics and procedure selection refinements.
Research Themes
- AI-enabled cardiovascular screening and diagnostics
- Ablation strategy optimization in persistent atrial fibrillation
- Scalable imaging workflows and access
Selected Articles
1. Development and multinational validation of an ensemble deep learning algorithm for detecting and predicting structural heart disease using noisy single-lead electrocardiograms.
A noise‑resilient deep learning model using single‑lead ECG (lead I) detected structural heart disease with AUROC ~0.88 and generalized across multiple external cohorts, including ELSA‑Brasil. Among patients without baseline SHD, high model probability predicted a 2.8–5.7‑fold higher incidence of future SHD, supporting use as a predictive biomarker.
Impact: This work operationalizes community‑scale screening and risk stratification for structural heart disease using wearable‑compatible single‑lead ECGs with robust external validation, bridging precision AI with public health applicability.
Clinical Implications: Enables scalable, low‑friction SHD screening and longitudinal risk monitoring in primary care and remote settings. May prompt earlier echocardiographic evaluation and targeted referral of high‑risk individuals.
Key Findings
- Single-lead AI achieved AUROC 0.879 for SHD detection with good calibration in the test set.
- External performance was consistent (AUROC 0.852–0.891 across US hospitals; 0.859 in ELSA-Brasil).
- High ADAPT-HEART probability predicted 2.8–5.7-fold higher risk of future SHD among those without baseline SHD.
Methodological Strengths
- Very large development cohort with paired echocardiography and multi-site external validation
- Noise-resilient single-lead design suited to wearable/portable devices with calibration assessment
Limitations
- Composite SHD label may mask disease-specific performance nuances
- Observational development/validation without prospective implementation or clinical impact trial
Future Directions: Prospective implementation trials assessing triage efficiency, downstream imaging yield, patient outcomes, and cost‑effectiveness; disease‑specific fine‑tuning and integration into remote monitoring pathways.
AIMS: Artificial intelligence (AI)-enhanced 12-lead electrocardiogram (ECG) can detect a range of structural heart diseases (SHDs); however, it has a limited role in community-based screening. We developed and externally validated a noise-resilient single-lead AI-ECG algorithm that can detect SHDs and predict the risk of their development using wearable/portable devices. METHODS AND RESULTS: Using 266 740 ECGs from 99 205 patients with paired echocardiographic data at Yale New Haven Hospital, we developed AI Deep learning for Adapting Portable Technology in HEART disease detection (ADAPT-HEART), a noise-resilient, deep learning algorithm, to detect SHDs using lead I ECG. SHD was defined as a composite of having a left ventricular ejection fraction of < 40%, moderate or severe left-sided valvular disease, and severe left ventricular hypertrophy. ADAPT-HEART was validated in four community hospitals in USA, and the population-based cohort of ELSA-Brasil. We assessed the model's performance as a predictive biomarker among those without baseline SHD across hospital-based sites and the UK Biobank. The development population had a median age of 66 [interquartile range, 54-77] years and included 49 947 (50.3%) women, with 18 896 (19.0%) having any SHD. ADAPT-HEART had an area under the receiver operating characteristics curve (AUROC) of 0.879 (95% confidence interval, 0.870-0.888) with good calibration for detecting SHD in the test set, and consistent performance in hospital-based external sites (AUROC: 0.852-0.891) and ELSA-Brasil (AUROC: 0.859). Among individuals without baseline SHD, high vs. low ADAPT-HEART probability conferred a 2.8- to 5.7-fold increase in the risk of future SHD across data sources (all CONCLUSION: We propose a novel model that detects and predicts a range of SHDs from noisy single-lead ECGs obtainable on portable/wearable devices, providing a scalable strategy for community-based screening and risk stratification for SHD.
2. Cryoballoon vs radiofrequency ablation in persistent atrial fibrillation: the CRRF-PeAF trial.
In a 12‑center RCT (n=499), cryoballoon ablation was non‑inferior to radiofrequency ablation for 1‑year atrial arrhythmia recurrence after a 90‑day blanking period. Radiofrequency produced greater left atrial reverse remodeling (larger reduction in LAVI), suggesting potential mechanistic differences despite similar rhythm outcomes.
Impact: High-quality randomized evidence in persistent AF informs first‑line energy selection, demonstrating similar rhythm efficacy while highlighting remodeling differences that may influence long‑term substrate modification strategies.
Clinical Implications: Cryoballoon is a valid alternative to radiofrequency as first‑line ablation for persistent AF; centers may individualize technique based on anatomy, workflow, and the observed differences in left atrial reverse remodeling.
Key Findings
- Primary endpoint (1-year atrial tachyarrhythmia) was 22.5% with cryoballoon vs 23.2% with radiofrequency; non-inferiority met (HR 0.99).
- Radiofrequency achieved greater reduction in left atrial volume index at 1 year (−11 vs −4 mL/m2; P<0.001).
- Trial randomized 500 patients across 12 centers with intention-to-treat analysis and a 90-day blanking period.
Methodological Strengths
- Multicenter randomized non-inferiority design with ITT analysis
- Clinically meaningful endpoints and structural remodeling assessment (LAVI)
Limitations
- Details of blinding and lesion set standardization not specified in the abstract
- Remodeling differences were not linked to long-term clinical outcomes beyond 1 year
Future Directions: Longer-term follow-up to relate reverse remodeling differences to durability, heart failure outcomes, and atrial myopathy; mechanistic imaging and lesion characterization to optimize energy selection.
BACKGROUND AND AIMS: There are limited prospective data on the efficacy, safety, and impact on reverse remodelling of cryoballoon ablation as compared to radiofrequency ablation for persistent atrial fibrillation. METHODS: A prospective, multicentre, randomized, non-inferiority clinical trial was conducted to compare the efficacy and safety of cryoballoon vs radiofrequency ablation for persistent atrial fibrillation. A total of 500 patients with persistent atrial fibrillation were randomized across 12 centres. The primary endpoint was the occurrence of atrial tachyarrhythmias at 1 year with a 90-day blanking period after ablation. RESULTS: The final analysis included 499 patients, with a median age of 69 years (interquartile range, 61-74); 249 patients were allocated to the cryoballoon group, and 250 to the radiofrequency group. In the intention-to-treat analysis, the primary endpoint was observed in 56 patients (22.5%) in the cryoballoon group and 58 (23.2%) in the radiofrequency group, and the cryoballoon group demonstrated non-inferiority compared to the radiofrequency group for the primary endpoint (hazard ratio .99; 95% confidence interval, .69-1.43; P = .96). The radiofrequency group showed a greater reduction in left atrial size (left atrial volume index) at 1 year than the cryoballoon group [-11 mL/m2 (interquartile range, -19 to -4) vs -4 mL/m2 (interquartile range, -13 to 3), P < .001]. CONCLUSIONS: In this randomized trial, cryoballoon ablation was non-inferior to radiofrequency ablation for the occurrence of atrial tachyarrhythmias at 1 year in patients with persistent atrial fibrillation.
3. Artificial intelligence fully automated analysis of handheld echocardiography in real-world patients with suspected heart failure.
In a multicenter, prospective, real‑world cohort (n=867), fully automated AI analysis of handheld echocardiograms detected LVEF ≤40% with diagnostic accuracy of 0.93 and was interchangeable with expert cart‑based human analysis. Although AI yielded analyzable LVEF in 61% of handheld scans, its accuracy matched expert benchmarks when analyzable.
Impact: Demonstrates scalable, automated LVEF assessment from handheld devices with expert‑level accuracy, addressing access bottlenecks in heart failure evaluation and enabling point‑of‑care triage.
Clinical Implications: Supports point‑of‑care handheld echo combined with AI to accelerate HF diagnosis and triage for reduced LVEF, potentially shortening time‑to‑treatment and optimizing imaging workflows.
Key Findings
- AI analysis of handheld echo achieved diagnostic accuracy of 0.93 (95% CI 0.90–0.95) for LVEF ≤40%.
- Interchangeability with expert cart-based LVEF was demonstrated (IEC −0.40; 95% CI −0.60 to −0.16).
- AI yielded LVEF in 61% of handheld vs 77% of cart-based scans; human analyses succeeded in 76% and 77%, respectively.
Methodological Strengths
- Prospective multicenter real-world design with paired handheld and cart-based exams
- Dual benchmarking against expert readers and equivalence analysis (IEC)
Limitations
- Lower analyzability on handheld scans (61%) may limit universal applicability without acquisition guidance
- Study focused on LVEF; broader valvular and right heart parameters were not detailed
Future Directions: Integrate real‑time acquisition guidance to improve analyzability; expand to comprehensive echo parameters; evaluate time‑to‑diagnosis, outcomes, and cost‑effectiveness in implementation studies.
AIMS: Echocardiography is a rate-limiting step in the timely diagnosis of heart failure (HF). Automated reporting of echocardiograms has the potential to streamline workflow. The aim of this study was to test the diagnostic accuracy of fully automated artificial intelligence (AI) analysis of images acquired using handheld echocardiography and its interchangeability with expert human-analysed cart-based echocardiograms in a real-world cohort with suspected HF. METHODS AND RESULTS: In this multicentre, prospective, observational study, patients with suspected HF had two echocardiograms: one handheld portable and one cart-based scan. Both echocardiograms were analysed using fully automated AI software and by human expert sonographers. The primary endpoint was the diagnostic accuracy of AI-automated analysis of handheld echocardiography to detect left ventricular ejection fraction (LVEF) ≤40%. Other endpoints included the interchangeability (assessed using individual equivalence coefficient [IEC]), between AI-automated and human analysis of cart-based LVEF. A total of 867 patients participated. The AI-automated analysis produced an LVEF in 61% of the handheld scans and 77% of the cart-based scans, compared to 76% and 77% of human analyses of the handheld and cart-based scans, respectively. The AI-automated analysis of handheld echocardiography had a diagnostic accuracy of 0.93 (95% confidence interval [CI] 0.90, 0.95) for identifying LVEF ≤40% (compared to the human analysis of cart-based transthoracic echocardiography scans). AI-automated analysis of LVEF on handheld devices was interchangeable with cart-based LVEF reported by two expert humans (IEC -0.40, 95% CI -0.60, -0.16). CONCLUSIONS: Artificial intelligence-automated analysis of handheld echocardiography had good diagnostic accuracy for detecting LVEF ≤40%. AI-automated analysis of LVEF of handheld scans was interchangeable with cart-based expert human analysis.